https://sciex.com/content/SCIEX/na/us/en


Struggling to Analyze Small Volume Samples with Conventional LC-MS?

Oct 25, 2016 | Blogs, Technology | 0 comments

The M3 MicroLC System is designed for scientists who are struggling to analyze small volume samples with conventional LC-MS and need to lower their limits of quantitation while maintaining throughput and robustness.

When designing the M3 MicroLC System, we focused on creating an easy-to-use LC that would make microflow LC simple – even for those new to the technique.

With the M3 MicroLC System you can:

  • Stop worrying about having enough sample for accurate quantitation with lower LLOQs
  • Reduce solvent usage from liters to milliliters
  • Have enough sample left over to run replicates to confirm results
  • Increase robustness and sample cleanliness with the trap-and-elute workflow

We are also pleased to announce that the MicroLC System is the recipient of the 2016 Instrument Business Outlook’s (IBO) Silver Analytical Instrument Industrial Design Award. Each year Instrument Business Outlook (IBO) announces their awards for excellence in the industrial design of analytical instruments, portable analytical instruments, and laboratory equipment. The winners of the 2016 Awards demonstrate how industrial design can improve a product’s functionality and the end user’s experience. Criteria include innovation, aesthetics, functionality and utility. Award candidates are chosen from the new products that IBO monitors through trade shows, trade publications, press releases and the Internet. Read more about this award >

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial